Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19

Marta Bodro, Frederic Cofan, J Ríos, Sabina Herrera, Laura Linares, María Ángeles Marcos, Alex Soriano, Asunción Moreno, Fritz Diekmann

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

11 Cites (Scopus)

Resum

In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed.
Idioma originalAnglès
Número d’article1551
Nombre de pàgines10
RevistaJournal of clinical medicine
Volum10
Número8
Data online anticipada7 d’abr. 2021
DOIs
Estat de la publicacióPublicada - d’ag. 2021

Fingerprint

Navegar pels temes de recerca de 'Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19'. Junts formen un fingerprint únic.

Com citar-ho